Harms and benefits of sodium-glucose co-transporter 2 inhibitors.
作者信息
Chesterman Thomas, Thynne Tilenka Rj
机构信息
Southern Adelaide Diabetes and Endocrine Service, South Australia Health.
College of Medicine and Public Health, Flinders University.
出版信息
Aust Prescr. 2020 Oct;43(5):168-171. doi: 10.18773/austprescr.2020.049. Epub 2020 Oct 1.
Abstract
摘要
相似文献
1
Harms and benefits of sodium-glucose co-transporter 2 inhibitors.
Aust Prescr. 2020 Oct;43(5):168-171. doi: 10.18773/austprescr.2020.049. Epub 2020 Oct 1.
2
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Drugs. 2015 Jan;75(1):33-59. doi: 10.1007/s40265-014-0337-y.
3
Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Postgrad Med. 2014 Oct;126(6):33-48. doi: 10.3810/pgm.2014.10.2819.
4
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Lancet Diabetes Endocrinol. 2017 Sep;5(9):709-717. doi: 10.1016/S2213-8587(17)30258-9. Epub 2017 Aug 3.
5
Cardio-renal protection with empagliflozin.
Ann Transl Med. 2016 Oct;4(20):409. doi: 10.21037/atm.2016.10.36.
6
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
Drugs Context. 2014 Dec 19;3:212264. doi: 10.7573/dic.212264. eCollection 2014.
7
Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression.
J Am Heart Assoc. 2021 Sep 21;10(18):e019918. doi: 10.1161/JAHA.120.019918. Epub 2021 Sep 13.
8
Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature.
Cardiol Res. 2021 Aug;12(4):210-218. doi: 10.14740/cr1268. Epub 2021 Jun 5.
9
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Vasc Health Risk Manag. 2016 Oct 27;12:393-405. doi: 10.2147/VHRM.S111991. eCollection 2016.
10
Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
Adv Ther. 2017 Feb;34(2):436-451. doi: 10.1007/s12325-016-0457-8. Epub 2016 Dec 15.
引用本文的文献
1
Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology.
Cells. 2025 Mar 6;14(5):387. doi: 10.3390/cells14050387.
2
Effect of the sodium-glucose cotransporter-2 inhibitor, DWP16001, as an add-on therapy to insulin for diabetic dogs: A pilot study.
Vet Med Sci. 2024 May;10(3):e1454. doi: 10.1002/vms3.1454.
3
Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Risk of Cardiovascular Diseases: A Systematic Review.
Cureus. 2023 Aug 24;15(8):e44054. doi: 10.7759/cureus.44054. eCollection 2023 Aug.
4
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options.
Molecules. 2023 Mar 30;28(7):3094. doi: 10.3390/molecules28073094.
5
Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) during the month of Ramadan in patients with type 2 diabetes mellitus in Pakistani population-an observational study from a tertiary care center in Karachi.
Endocrine. 2023 Apr;80(1):64-70. doi: 10.1007/s12020-022-03290-7. Epub 2022 Dec 29.
6
Diuretics in the management of chronic heart failure: when and how.
Aust Prescr. 2022 Dec;45(6):200-204. doi: 10.18773/austprescr.2022.069. Epub 2022 Nov 30.
7
Sodium-glucose co-transporter 2 inhibitors beyond diabetes.
Aust Prescr. 2022 Aug;45(4):121-124. doi: 10.18773/austprescr.2022.036. Epub 2022 Aug 1.
8
Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2-Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes.
Healthcare (Basel). 2022 Jun 21;10(7):1153. doi: 10.3390/healthcare10071153.
本文引用的文献
1
Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.
Am J Cardiol. 2019 Dec 15;124 Suppl 1:S45-S52. doi: 10.1016/j.amjcard.2019.10.029.
2
Fournier's gangrene and sodium-glucose co-transporter-2 inhibitors: A meta-analysis of randomized controlled trials.
Diabetes Obes Metab. 2020 Feb;22(2):272-275. doi: 10.1111/dom.13900. Epub 2019 Nov 20.
3
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
4
Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases.
Ann Intern Med. 2019 Jun 4;170(11):764-769. doi: 10.7326/M19-0085. Epub 2019 May 7.
5
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
6
SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3077-3087. doi: 10.1210/jc.2019-00139.
7
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
BMJ Open. 2019 Feb 1;9(1):e022577. doi: 10.1136/bmjopen-2018-022577.
8
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Diabetes Care. 2019 Jun;42(6):1147-1154. doi: 10.2337/dc18-2316. Epub 2019 Feb 6.
9
Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials.
CMAJ Open. 2018 Dec 10;6(4):E594-E602. doi: 10.9778/cmajo.20180111. Print 2018 Oct-Dec.
10
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10.
Zotero 插件